Company: IXHL
Filing Date: 2025-04-17
Form Type: PRER14A
Source: 0001213900-25-033013
Chunk: 50

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-17
Form: PRER14A
Chunk 50
---
 Officer                         |     |                        |         — |
| All Current Executive Officers as a group                       |     |                        | 1,390,793 |
| All Current Directors who are not executive officers as a group |     |                        |   970,000 |
| Each other person who received 5% of such                       
 awards                                                          |     |                        |           |
| Troy Valentine, Chairperson                                     |     |                        |   670,000 |
| All Employees who are not executive officers as a group         |     |                        |    88,659 |

| (1) | The named executive officers above include the most highly compensated                     
 executive officers other than our chief executive officer and our chief financial officer. |

In addition to the above referenced restricted
stock units granted under the 2023 Plan, options to purchase an aggregate of 100,004 shares of our common stock having a weighted-average
exercise price of $12.64 are held by Joel Latham, options to purchase an aggregate of 28,002 shares of our common stock having a weighted-average
exercise price of 20.16 are held by Troy Valentine, options to purchase an aggregate of 3,000 shares of our common stock having a weighted-average
exercise price of $20.16 are held by Joseph Swan and options to purchase an aggregate of 50,000 shares of our common stock having a weighted-average
exercise price of $82.19 are held by Robert Clark, each of which was issued outside of the 2023 Plan prior to the Company’s November
28, 2023 the domiciliation from Australia to Delaware.

The amounts of future awards under the Amended 2023
Plan are not determinable and will be granted at the sole discretion of the board of directors or the Committee, including grants to our
named executive officers, our current executive officers, our current directors who are not executive officers, and employees who are
not executive officers.

On April 15, 2025, the closing market price per
share of our common stock was $0.61 as reported by Nasdaq.

Required Vote

The affirmative vote of a majority of the shares
of common stock present or represented by proxy and entitled to vote on the subject matter is required to approve this proposal. Abstentions
will count as votes AGAINST this proposal. Broker non-votes will have no effect on this proposal. Brokerage firms do not have authority
to vote customers’ unvoted shares held by the firms in street name